News

Intercept to Announce Second Quarter 2023 Financial Results on August 2, 2023

MORRISTOWN, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and…

1 year ago

Ocuphire to Present at American Society of Retina Specialists Annual Meeting and OIS Retina Innovation Summit

ASRS presentations will feature data from ZETA-1 Phase 2 trial evaluating APX3330 in diabetic retinopathy End-of-Phase 2 meeting with FDA…

1 year ago

BrainsWay to Report Second Quarter 2023 Financial Results on August 9, 2023

BURLINGTON, Mass. and JERUSALEM, July 26, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),…

1 year ago

Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress

DUBLIN, Ireland and BRIDGEWATER, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the acceptance of…

1 year ago

Ardelyx to Report Second Quarter 2023 Financial Results on August 2, 2023

Conference call scheduled for 8:00 a.m. Eastern TimeWALTHAM, Mass., July 26, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a…

1 year ago

AI Empowers Researchers to Bring Precision Medicine to Post-stroke Speech and Cognitive Rehabilitation

Constant Therapy Health grants researchers at Boston University and The University of Texas at Austin access to world’s largest speech…

1 year ago

Nephros Schedules Second Quarter 2023 Financial Results Conference Call

SOUTH ORANGE, NJ, July 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (Nasdaq: NEPH), a leading water technology…

1 year ago

Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors

BOSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a clinical stage biotechnology company developing novel…

1 year ago

Atlas Global Brands Debuts Brand Partnership with Snoop Dogg D*gg lbs to Launch in Israel This Summer

First shipment of D*gg lbs (pronounced “dog pounds”) from the Company’s EU GMP facility in Chatham, Ontario has arrived in…

1 year ago

Inozyme Pharma Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency

- Change in plasma pyrophosphate (PPi) as primary endpoint in the U.S. and co-primary endpoint in the EU for planned…

1 year ago